Details of the Drug

General Information of Drug (ID: DMA5XGH)

Drug Name

Isradipine

Synonyms

Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]
Herpes simplex virus infection	1F00	Phase 3	[3]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

371.4

Topological Polar Surface Area (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 26 mL/min/kg [5]
Elimination: 0% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 hours [5]
Metabolism: The drug is metabolized via the hepatic [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.76928 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.04% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.008 mg/mL [4]

Chemical Identifiers

Formula: C19H21N3O5
IUPAC Name: 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
InChI: InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChIKey: HMJIYCCIJYRONP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3784
ChEBI ID: CHEBI:6073
CAS Number: 75695-93-1
DrugBank ID: DB00270
TTD ID: D0Z7KE
VARIDT ID: DR00975
ACDINA ID: D00336

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Modulator	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Isradipine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Acebutolol	DM0TI4U	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Acebutolol.	Hypertension [BA00-BA04]	[18]
Bisoprolol	DM3UZ95	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Bisoprolol.	Hypertension [BA00-BA04]	[18]
Penbutolol	DM4ES8F	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Penbutolol.	Hypertension [BA00-BA04]	[18]
Nebivolol	DM7F1PA	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Nebivolol.	Hypertension [BA00-BA04]	[18]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Isradipine caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[19]
Pindolol	DMD2NV7	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Pindolol.	Hypertension [BA00-BA04]	[18]
Labetalol	DMK8U72	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Labetalol.	Hypertension [BA00-BA04]	[18]
Atenolol	DMNKG1Z	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Atenolol.	Hypertension [BA00-BA04]	[18]
-----------


⏷ Show the Full List of 8 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Isradipine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Isradipine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[20]
Arn-509	DMT81LZ	Major	Increased metabolism of Isradipine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[21]
Magnesium Sulfate	DMVEK07	Moderate	Additive neuromuscular blocking effects by the combination of Isradipine and Magnesium Sulfate.	Acute pain [MG31]	[22]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Isradipine due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[23]
Mitotane	DMU1GX0	Major	Increased metabolism of Isradipine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[21]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Isradipine due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[23]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Isradipine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[24]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Isradipine and Promazine.	Appearance/behaviour symptom [MB23]	[25]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Isradipine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[26]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Isradipine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[26]
Zileuton	DMVRIC2	Minor	Decreased metabolism of Isradipine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[27]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Isradipine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Isradipine and Linezolid.	Bacterial infection [1A00-1C4Z]	[29]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Isradipine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[30]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Isradipine and Cariprazine.	Bipolar disorder [6A60]	[25]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Isradipine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[31]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Isradipine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Isradipine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
Grepafloxacin	DMGLX0T	Moderate	Decreased metabolism of Isradipine caused by Grepafloxacin mediated inhibition of CYP450 enzyme.	Bronchitis [CA20]	[34]
Sotalol	DML60TN	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Sotalol.	Cardiac arrhythmia [BC9Z]	[18]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Isradipine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[24]
Methohexital	DM7YMIT	Moderate	Increased metabolism of Isradipine caused by Methohexital mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[24]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Isradipine caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[24]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Isradipine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[35]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Isradipine and Pasireotide.	Cushing syndrome [5A70]	[36]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Isradipine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[21]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Isradipine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[37]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Isradipine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[38]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Isradipine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[39]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Isradipine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[36]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Isradipine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[40]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Isradipine and Selegiline.	Depression [6A70-6A7Z]	[29]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Isradipine and Isocarboxazid.	Depression [6A70-6A7Z]	[29]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Isradipine and Tranylcypromine.	Depression [6A70-6A7Z]	[29]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Isradipine and OPC-34712.	Depression [6A70-6A7Z]	[25]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Isradipine and Phenelzine.	Depression [6A70-6A7Z]	[29]
Primidone	DM0WX6I	Major	Increased metabolism of Isradipine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Isradipine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Isradipine caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Isradipine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Isradipine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Isradipine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Isradipine caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Isradipine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Isradipine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[45]
Timolol	DM3NXRU	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Timolol.	Essential hypertension [BA00]	[18]
Nadolol	DMW6GVL	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Nadolol.	Essential hypertension [BA00]	[18]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Isradipine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[46]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Isradipine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[26]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Isradipine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[26]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Isradipine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[28]
Carteolol	DMFMDOB	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Carteolol.	Glaucoma [9C61]	[18]
Metipranolol	DMJMVKI	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Metipranolol.	Glaucoma [9C61]	[47]
Levobetaxolol	DMSREPX	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Levobetaxolol.	Glaucoma [9C61]	[47]
Levobunolol	DMTNFCQ	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Levobunolol.	Glaucoma [9C61]	[47]
Carvedilol	DMHTEAO	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Carvedilol.	Heart failure [BD10-BD1Z]	[18]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Isradipine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[48]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Isradipine due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[49]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Isradipine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[48]
Rifampin	DMA8J1G	Major	Increased metabolism of Isradipine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[21]
Rifapentine	DMCHV4I	Major	Increased metabolism of Isradipine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[21]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Isradipine and Procarbazine.	Hodgkin lymphoma [2B30]	[29]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Isradipine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Isradipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Isradipine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Isradipine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Isradipine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Isradipine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Isradipine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Isradipine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Isradipine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Isradipine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Isradipine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[59]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Isradipine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[60]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Isradipine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[61]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Isradipine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[24]
Pentobarbital	DMFNH7L	Moderate	Increased metabolism of Isradipine caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[24]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Isradipine and Propiomazine.	Insomnia [7A00-7A0Z]	[25]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Isradipine and ITI-007.	Insomnia [7A00-7A0Z]	[25]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Isradipine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[62]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Isradipine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Isradipine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[63]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Isradipine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[64]
LGX818	DMNQXV8	Moderate	Increased metabolism of Isradipine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[65]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Isradipine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[23]
Propranolol	DM79NTF	Moderate	Increased risk of cardiac depression by the combination of Isradipine and Propranolol.	Migraine [8A80]	[18]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Isradipine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[66]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Isradipine and Thalidomide.	Multiple myeloma [2A83]	[35]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Isradipine and Siponimod.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Isradipine and Fingolimod.	Multiple sclerosis [8A40]	[67]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Isradipine and Ozanimod.	Multiple sclerosis [8A40]	[68]
Rifabutin	DM1YBHK	Major	Increased metabolism of Isradipine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[21]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Isradipine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[23]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Isradipine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[69]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Isradipine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[70]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Isradipine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[71]
Modafinil	DMYILBE	Moderate	Increased metabolism of Isradipine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[35]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Isradipine and Prochlorperazine.	Nausea/vomiting [MD90]	[25]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Isradipine and Promethazine.	Nausea/vomiting [MD90]	[25]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Isradipine and Thiethylperazine.	Nausea/vomiting [MD90]	[25]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Isradipine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[72]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Isradipine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[73]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Isradipine and Safinamide.	Parkinsonism [8A00]	[29]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Isradipine and Rasagiline.	Parkinsonism [8A00]	[29]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Isradipine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[74]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Isradipine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[75]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Isradipine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[76]
Enzalutamide	DMGL19D	Major	Increased metabolism of Isradipine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[21]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Isradipine due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[23]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Isradipine due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[23]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Isradipine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[25]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Isradipine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[25]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Isradipine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[25]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Isradipine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[77]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Isradipine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[78]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Isradipine due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[23]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Isradipine due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[23]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Isradipine due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[23]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Isradipine due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[23]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Isradipine due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[23]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Isradipine and Quetiapine.	Schizophrenia [6A20]	[25]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Isradipine and Mesoridazine.	Schizophrenia [6A20]	[25]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Isradipine and Thioridazine.	Schizophrenia [6A20]	[25]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Isradipine and Aripiprazole.	Schizophrenia [6A20]	[25]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Isradipine and Iloperidone.	Schizophrenia [6A20]	[25]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Isradipine and Paliperidone.	Schizophrenia [6A20]	[25]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Isradipine and Loxapine.	Schizophrenia [6A20]	[25]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Isradipine and Haloperidol.	Schizophrenia [6A20]	[25]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Isradipine and Perphenazine.	Schizophrenia [6A20]	[25]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Isradipine and Molindone.	Schizophrenia [6A20]	[25]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Isradipine and Chlorpromazine.	Schizophrenia [6A20]	[25]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Isradipine and Thiothixene.	Schizophrenia [6A20]	[25]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Isradipine and Clozapine.	Schizophrenia [6A20]	[25]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Isradipine and Trifluoperazine.	Schizophrenia [6A20]	[25]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Isradipine and Risperidone.	Schizophrenia [6A20]	[25]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Isradipine and Amisulpride.	Schizophrenia [6A20]	[25]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Isradipine and Asenapine.	Schizophrenia [6A20]	[25]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Isradipine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[79]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Isradipine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[23]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Isradipine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Armodafinil	DMGB035	Moderate	Increased metabolism of Isradipine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
LEE011	DMMX75K	Moderate	Decreased metabolism of Isradipine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[80]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Isradipine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[23]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Isradipine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[81]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Isradipine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[78]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Isradipine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[78]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Isradipine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[25]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Isradipine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[82]
-----------


⏷ Show the Full List of 148 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Isradipine 5 mg capsule	5 mg	Oral Capsule	Oral
Isradipine 2.5 mg capsule	2.5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077169.
3	ClinicalTrials.gov (NCT00367211) Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
10	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
11	RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
12	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
13	Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
14	Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
15	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
17	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
18	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
19	Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
20	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
21	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
22	Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
23	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24	Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
25	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
26	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
27	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
28	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
29	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
30	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
31	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
32	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
33	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
34	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
35	Cerner Multum, Inc. "Australian Product Information.".
36	Canadian Pharmacists Association.
37	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
38	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
39	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
40	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
41	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
42	Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
43	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
44	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
45	Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
46	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
47	Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
48	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
49	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
50	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
51	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
52	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
53	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
54	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
55	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
56	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
57	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
58	Olkkola KT, Palkama VJ, Neuvonen PJ "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life." Anesthesiology 91 (1999): 681-5. [PMID: 10485779]
59	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
60	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
61	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
62	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
64	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
65	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
66	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
67	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
68	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
69	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
70	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
71	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
72	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
73	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
74	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
75	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
76	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
77	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
78	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
79	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
80	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
81	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
82	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.